2023
Barriers to Care Among Sexual and Gender Minority Individuals With Chronic Inflammatory Skin Diseases in the US
Nock M, Kamal K, Zampella J, Roberson M, Cohen J, Barbieri J. Barriers to Care Among Sexual and Gender Minority Individuals With Chronic Inflammatory Skin Diseases in the US. JAMA Dermatology 2023, 159: 1323-1331. PMID: 37755822, PMCID: PMC10535014, DOI: 10.1001/jamadermatol.2023.3328.Peer-Reviewed Original ResearchConceptsChronic inflammatory skin diseaseInflammatory skin diseaseHealth care practitionersCross-sectional studySGM patientsPrevalence of barriersCare practitionersGender minority patientsSkin diseasesMinority patientsMAIN OUTCOMEHealth careMultivariable logistic regressionHealth care accessMental health careSpecialist careCare accessPatientsUs Research ProgramLogistic regressionCarePrevalenceDiseaseNational InstituteGender minority individuals
2016
Cost-effectiveness of Confirmatory Testing Before Treatment of Onychomycosis
Mikailov A, Cohen J, Joyce C, Mostaghimi A. Cost-effectiveness of Confirmatory Testing Before Treatment of Onychomycosis. JAMA Dermatology 2016, 152: 1-6. PMID: 26716567, DOI: 10.1001/jamadermatol.2015.4190.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdministration, TopicalAlgorithmsCost SavingsCost-Benefit AnalysisDecision Support TechniquesDecision TreesHealth Care CostsHumansHydroxidesNaphthalenesOnychomycosisPeriodic Acid-Schiff ReactionPotassium CompoundsPotentially Inappropriate Medication ListTerbinafineTriazolesConceptsConfirmatory testingOral terbinafineSystemic therapyDirect patient evaluationLiver toxic effectsPatient cost savingsPotassium hydroxide (KOH) stainDisease prevalenceTreatment of onychomycosisConfirmatory diagnostic testingHealth care professionalsPrevalence of diseaseTerbinafine therapyEmpirical therapyPretreatment testingPrimary outcomePatient evaluationSpecific therapyEmpirical treatmentMAIN OUTCOMECare professionalsInternational guidelinesTherapyDiagnostic testingPatient safety